{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:55:59Z","timestamp":1777949759821,"version":"3.51.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Bone-seeking radiopharmaceuticals are the treatment of choice with clinical benefits for patients with extensive skeletal metastases, but they can also cause serious radiation-related adverse events (rrAEs). Management of rare and severe radiopharmaceutical rrAEs remains challenging because of incomplete knowledge of their natural history and pathogenetic mechanisms. We report a case of unlikely related gangrene following a protracted hospitalization after one dose of investigational [\n                      <jats:sup>117m<\/jats:sup>\n                      Sn]tin-117m-diethylenetriaminepentaacetic acid (Sn-117m-DTPA) for treatment of extensive skeletal metastases from castration-resistant prostate cancer (mCRPC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      An 80-year-old man with innumerable painful skeletal metastases from mCRPC developed anorexia and bilateral ankle edema with serous-draining skin fissures of the left foot, worrisome for uninfected dry gangrene, 24 days after receiving a single administration of Sn-117m-DTPA (710 MBq) in a phase II clinical trial (NCT04616547). Laboratory investigations revealed leukopenia (3,180 ml\n                      <jats:sup>\u22121<\/jats:sup>\n                      ). Thirteen days later (cycle 1, day 37), he reported anorexia, chills, and generalized weakness, and also had bilateral pedal gangrene. Emergent left above-the-knee amputation and right transphalangeal (ray 2) amputation revealed tissue necrosis complicated by blistering and foul-smelling discharge. He developed postsurgical respiratory decompensation requiring intubation, vasopressors, and broad-spectrum antibiotics. Despite escalating supportive care and enteral feeding, only limited improvement was observed during hospitalization lasting more than 1 month. Five weeks after the onset of pedal gangrene, the patient succumbed to sepsis attributed to a methicillin-sensitive\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      aspiration pneumonia. No autopsy was performed. Remarkably, prior to these events and at sites of skeletal metastases from mCRPC, he reported a substantial reduction in pain (from a score of 7 to 3 on an 11-point scale) and reduced use of oral narcotic analgesia (from three to two times daily).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Gangrene, complicated by leukopenia and sepsis from aspiration pneumonia, is a rarely reported serious adverse event occurring late after a radiopharmaceutical treatment. Given that the window of reversibility for gangrene is narrow, prompt and decisive intervention is warranted. Subtle perturbations in skin integrity after radiopharmaceutical treatment may be more prevalent than realized and should be addressed in both clinical and investigational settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1799473","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:25:30Z","timestamp":1777868730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Gangrene after one dose of investigational stannic pentetate radiopharmaceutical"],"prefix":"10.3389","volume":"16","author":[{"given":"Zin W.","family":"Myint","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riham H.","family":"El Khouli","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine\/Molecular Imaging and Radiotheranostics, Department of Radiology, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan P.","family":"Lemieux","sequence":"additional","affiliation":[{"name":"Radiation Safety, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles A.","family":"Kunos","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine, University of Kentucky","place":["Lexington, KY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.22742","article-title":"Distribution of metastatic sites in patients with prostate cancer: a population-based analysis","volume":"74","author":"Gandaglia","year":"2014","journal-title":"Prostate"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.51.7219","article-title":"Pain and nociception: mechanisms of cancer-induced bone pain","volume":"32","author":"Falk","year":"2014","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23967","article-title":"Optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines","volume":"80","author":"Shore","year":"2020","journal-title":"Prostate"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0356","article-title":"Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: phase 3 results of NRG Oncology\/RTOG 0631 randomized clinical trial","volume":"9","author":"Ryu","year":"2023","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090070071032","article-title":"Evaluation of phosphorus-32 for intractable pain secondary to prostatic carcinoma metastases","volume":"193","author":"Joshi","year":"1965","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(93)90309-j","article-title":"Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer","volume":"25","author":"Porter","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B16","article-title":"Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I\/II trial","volume":"34","author":"Collins","year":"1993","journal-title":"J Nucl Med"},{"key":"B17","article-title":"Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo","volume":"32","author":"Maxon","year":"1991","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178673","article-title":"225Ac-PSMA-617 for PSMA-targeted \u03b1-radiation therapy of metastatic castration-resistant prostate cancer","volume":"57","author":"Kratochwil","year":"2016","journal-title":"J Nucl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0047-0740(85)90024-5","article-title":"The development and in-vivo behavior of tin containing radiopharmaceuticals--II. Autoradiographic and scintigraphic studies in normal animals and in animal models of bone disease","volume":"12","author":"Oster","year":"1985","journal-title":"Int J Nucl Med Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0969-8051(97)00180-7","article-title":"In-vivo tissue uptake and retention of Sn-117m(4+)DTPA in a human subject with metastatic bone pain and in normal mice","volume":"25","author":"Swailem","year":"1998","journal-title":"Nucl Med Biol"},{"key":"B23","article-title":"Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain","volume":"38","author":"Krishnamurthy","year":"1997","journal-title":"J Nucl Med"},{"key":"B24","article-title":"Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study","volume":"36","author":"Atkins","year":"1995","journal-title":"J Nucl Med"},{"key":"B25","article-title":"Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I\/II clinical study","volume":"4","author":"Srivastava","year":"1998","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12885-022-09496-2","article-title":"A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases","volume":"22","author":"Myint","year":"2022","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-4-7","article-title":"Topical treatment of radiation-induced dermatitis: current issues and potential solutions","volume":"9","author":"Iacovelli","year":"2020","journal-title":"Drugs Context"},{"key":"B29","article-title":"Radiation-induced arterial injuries","volume":"93","author":"McCready","year":"1983","journal-title":"Surgery"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-011-9580-0","article-title":"Glucocorticoid-induced osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5234.286","article-title":"Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis","volume":"270","author":"Auphan","year":"1995","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i21.7187","article-title":"Effects of glucocorticoids on leukocytes: genomic and non-genomic mechanisms","volume":"10","author":"Jia","year":"2022","journal-title":"World J Clin cases"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100845","article-title":"Half body irradiation (HBI) for bone metastases in the modern radiotherapy technique era - a systematic review","volume":"49","author":"Bilski","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/mou.0000000000001296","article-title":"Toxicities of taxane-based chemotherapy in prostate cancer","volume":"35","author":"Matsukawa","year":"2025","journal-title":"Curr Opin Urol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s1262-3636(07)70215-x","article-title":"Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease","volume":"31","author":"Carmona","year":"2005","journal-title":"Diabetes Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.avsg.2021.07.010","article-title":"Cohort study examining the association of immunosuppressant drug prescription with major adverse cardiovascular and limb events in patients with peripheral artery disease","volume":"78","author":"Golledge","year":"2022","journal-title":"Ann Vasc Surg"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.115.016424","article-title":"Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention","volume":"132","author":"Howard","year":"2015","journal-title":"Circulation"},{"key":"B38","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jvs.2025.08.037","article-title":"Smoking cessation duration is associated with the risk of amputation after revascularization for chronic limb-threatening ischemia","volume":"83","author":"Carter","year":"2026","journal-title":"J Vasc Surg"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-860874","article-title":"Arterial thromboembolic events preceding the diagnosis of cancer in older persons","volume":"133","author":"Navi","year":"2019","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jvs.2021.03.058","article-title":"A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer","volume":"74","author":"Govsyeyev","year":"2021","journal-title":"J Vasc Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket475","article-title":"Vasculitis associated with rheumatoid arthritis: a case-control study","volume":"53","author":"Makol","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200306000-00012","article-title":"188Re-tin-colloid as a new therapeutic agent for rheumatoid arthritis","volume":"24","author":"Lee","year":"2003","journal-title":"Nucl Med Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/vru.13198","article-title":"Clinical effectiveness and safety of intraarticular administration of a (117m)tin radiocolloid (Synovetin OA(TM)) for treatment of early and intermediate grade osteoarthritis of the elbow in a dose finding study conducted in 44 dogs","volume":"64","author":"Lattimer","year":"2023","journal-title":"Vet Radiol Ultrasound"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/hp.0000000000001579","article-title":"External radiation dose to owners of canines treated with (117m Sn) radiosynoviorthesis for osteoarthritis","volume":"123","author":"Smith","year":"2022","journal-title":"Health Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/ard.55.11.816","article-title":"Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis","volume":"55","author":"Fujikawa","year":"1996","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:25:31Z","timestamp":1777868731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1799473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":45,"alternative-id":["10.3389\/fonc.2026.1799473"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1799473","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"article-number":"1799473"}}